Pharmacogenetics: Anti-TNF therapy in RA--towards personalized medicine?

Cornelis L Verweij

doi:10.1038/nrrheum.2011.13

Pharmacogenetics: Anti-TNF therapy in RA--towards personalized medicine?

Nat Rev Rheumatol. 2011 Mar;7(3):136-8. doi: 10.1038/nrrheum.2011.13. Epub 2011 Feb 8.

Author

Cornelis L Verweij¹

Affiliation

¹ Departments of Pathology and Rheumatology, Section of Inflammatory Disease Profiling, VU University Medical Center, Amsterdam, The Netherlands. c.verweij@vumc.nl

PMID: 21304506
DOI: 10.1038/nrrheum.2011.13

Abstract

A substantial proportion of patients with rheumatoid arthritis do not respond to tumor necrosis factor blocking therapy. Results of a large genome-wide association study demonstrate evidence of novel genetic factors that determine response to treatment, which could provide a basis for individualizing therapy.

Publication types

Comment

MeSH terms

Adaptor Proteins, Signal Transducing / genetics
Arthritis, Rheumatoid / drug therapy*
Cell Adhesion Molecules
Humans
Neoplasm Proteins / genetics
Pharmacogenetics / trends*
Polymorphism, Single Nucleotide / genetics
Precision Medicine / trends*
Trans-Activators / genetics
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Adaptor Proteins, Signal Transducing
Cell Adhesion Molecules
EYA4 protein, human
Neoplasm Proteins
PDZD2 protein, human
Trans-Activators
Tumor Necrosis Factor-alpha